Aligos Therapeutics

Improving patient outcomes through best-in-class therapies for liver and viral diseases

Potential Functional Cure for Hepatitis B (HBV): HBV is still seen as a major public health crisis with more than 290 million chronic carriers globally. Chronic hepatitis B (CHB) is the primary cause of liver death worldwide and mortality rates continue to rise. Aligos is developing ALG-000184, the first novel, oral drug candidate for the treatment of HBV infection that can inhibit multiple components of the viral lifecycle, leading to more complete suppression of the virus compared to other current standards of care.
MASH is Hot Again: Following the approval of Madrigal’s Rezdiffra, the MASH space is heating up again with additional companies getting closer to the FDA finish line. Aligos is developing ALG-055009 as a potentially best-in-class THR-ß agonist, offering 5-50x greater potency than competitors with a focus on enhanced beta selectivity and optimized pharmacokinetics. Recent Phase 2a HERALD study data supports its superior safety profile with fewer side effects, positioning ALG-055009 as a frontrunner in MASH treatment and significantly improving patient outcomes.
Key Events in 2025: Data presentations on ALG-055009 & ALG-000184 at AASLD’s The Liver Meeting in November 2024; IND submission & initiation of a Phase 2 study of ALG-000184 for CHB expected in Q1-2025; Completion of activities required for a Phase 2b study of ALG-055009 in MASH expected by the middle of 2025